新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2025-047 新疆百花村医药集团股份有限公司 关于筹划控制权变更事项继续停牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 媒体披露的《新疆百花村医药集团股份有限公司关于筹划控制权变更事项的停牌 公告》（公告编号：2025-046）。 截至本公告披露日，上述事项仍处于筹划之中，公司控股股东、实际控制人 正与相关方积极推进本次事项的各项工作，公司预计无法在 2025 年 12 月 31 日 （星期三）开市起复牌。根据《上海证券交易所股票上市规则》《上海证券交易 所上市公司自律监管指引第 4 号——停复牌》等有关规定，经公司向上海证券交 易所申请，本公司股票将于 2025 年 12 月 31 日（星期三）开市起继续停牌，预 计继续停牌时间不超过 3 个交易日。 停牌期间，公司将根据上述事项进展情况，严格按照有关法律法规的规定和 要求履行信息披露义务。待上述事项确定后，公司将及时发布相关公告并申请公 ...

每经AI快讯，12月30日，百花医药（600721）公告，公司股票自2025年12月31日开市起继续停牌，预 计停牌时间不超过3个交易日，因公司控股股东、实际控制人米在齐先生、米恩华先生、杨小玲女士正 在筹划公司股份协议转让事宜，该事项可能导致公司控制权发生变更。目前相关方正积极推进本次交易 工作，尚存在不确定性。停牌期间，公司将严格按照有关法律法规的规定和要求履行信息披露义务。待 事项确定后，公司将及时发布相关公告并申请股票复牌。敬请广大投资者关注公司后续公告，并注意投 资风险。 ...

Core Viewpoint - The company is planning a share transfer by its controlling shareholder, which may lead to a change in control of the company [1] Group 1 - The controlling shareholder and actual controller of the company are in the process of planning a share transfer agreement [1] - This share transfer may result in a change of control over the company [1] - To ensure fair information disclosure and protect investor interests, the company's stock will remain suspended from trading starting December 31, 2025, with an expected suspension period of no more than three trading days [1]

Core Viewpoint - Baihua Pharmaceutical (600721.SH), a company specializing in pharmaceutical research and development services (CRO), announced that it received a notification from its controlling shareholders regarding the planning of a share transfer agreement, which may lead to a change in the company's control [1] Group 1 - The company is involved in the pharmaceutical research and development services sector [1] - The controlling shareholders include Mi Zaiqi, Mi Enhua, and Yang Xiaoling [1] - The potential share transfer could significantly impact the company's governance structure [1]

Core Viewpoint - The controlling family of Baihua Pharmaceutical (600721.SH), led by Mienhua Mi, is planning a potential transfer of shares that may lead to a change in the company's control [1] Group 1: Company Background - Baihua Pharmaceutical, originally known as "Baihua Village," was the first listed company of the Xinjiang Production and Construction Corps, with its stock listed on the Shanghai Stock Exchange in 1996 [2] - The company has undergone multiple asset restructurings, transitioning from retail and trade to pharmaceutical research and development services after acquiring Nanjing Huawai Pharmaceutical in 2016 [2] Group 2: Financial Performance - Baihua Pharmaceutical has experienced significant fluctuations in net profit from 2019 to 2024, with figures of 34.38 million, -320 million, 59.83 million, -34.76 million, 12.97 million, and 41.48 million yuan respectively [3] - In the first nine months of 2025, the company reported a revenue of 299 million yuan, a year-on-year increase of 2.74%, and a net profit of 32.67 million yuan, up 36.41% compared to the previous year [3] Group 3: Shareholding Changes - In December 2024, the controlling shareholder of Baihua Pharmaceutical changed, with the actual controllers now including Mienhua Mi, his son Mizanqi Mi, and Yang Xiaoling, holding a combined 20.71% of the total shares [1][2] - Following the change in control, the shareholding structure of Hualing Industrial Group also shifted, with Xinjiang Commerce and Logistics Asset Management Co., Ltd. becoming the controlling shareholder [4] Group 4: Future Outlook - Baihua Pharmaceutical has been suspended from trading since December 29, with expectations that the company's future direction will be clarified within 2025 [5]

Regulatory Developments - The National Medical Products Administration (NMPA) held a meeting on post-market regulation of medical devices, emphasizing the need for a balance between safety and industry vitality while planning for 2026 [1] - The NMPA approved the long-acting growth hormone injection, Nozeyou®, developed by Novo Nordisk, marking it as the first international original long-acting growth hormone for children in China [4] - Changchun High-tech's subsidiary, GenSci, received acceptance for a clinical trial application for GenSci141 ointment, which aims to address various hormonal deficiencies in children [5] - Jiukang Bio announced the acquisition of medical device registration certificates for two diagnostic kits, enhancing its product line in the in vitro diagnostic sector [6] Market Activities - Suzhou Tongxin Medical Technology's IPO application was accepted, with plans to raise 1.064 billion yuan for various projects including the production base for implantable left ventricular assist devices [8][9] - Zhendong Pharmaceutical announced a partnership to establish a fund focused on investments in the biopharmaceutical sector, contributing 30 million yuan as a limited partner [11] Corporate Changes - Baihua Pharmaceutical is planning a change in control, leading to a temporary suspension of its stock trading [10] - *ST Changyao is under investigation for alleged financial misconduct, which may lead to a forced delisting due to false financial reporting [18]

Core Viewpoint - Baihua Pharmaceutical (600721) announced a suspension of trading due to its controlling shareholders planning a share transfer that may lead to a change in control [1] Group 1: Share Transfer Announcement - The controlling shareholders, Mi Zaiqi, Mi Enhua, and Yang Xiaoling, are negotiating a share transfer that could change the company's control [1] - Trading of Baihua Pharmaceutical's stock will be suspended starting December 29, 2025, for no more than two trading days [1] - As of the last trading day, the stock price was 12.24 CNY per share, with a market capitalization of 4.707 billion CNY [1] Group 2: Historical Context and Financials - One year ago, the same shareholders acquired shares through a transfer, with a total of 79.53 million shares (20.71% of total shares) being transferred at a price of 6.8 CNY per share, totaling 541 million CNY [2] - The current share price represents an 80% increase from the previous transfer price, resulting in an unrealized gain of approximately 430 million CNY for the shareholders [2] - The company reported a revenue of 298.6 million CNY for the first three quarters of 2025, a year-on-year increase of 2.74%, and a net profit of 32.67 million CNY, up 36.41% year-on-year [3] Group 3: Business Model - Baihua Pharmaceutical's business model focuses on providing integrated services in drug discovery, clinical trials, and regulatory submissions, catering to diverse and personalized technical requirements of clients [3]

Group 1 - The National Venture Capital Guiding Fund has officially launched with a government investment of 100 billion yuan, expected to leverage over 1 trillion yuan in social capital for strategic emerging industries such as integrated circuits, artificial intelligence, and quantum technology [3] - The People's Bank of China (PBOC) emphasizes the need to improve the policy environment for long-term investments, aiming to increase the scale and proportion of medium- and long-term funds invested in A-shares [4] - The Shanghai Stock Exchange has released guidelines to support commercial rocket companies, allowing them to list on the Sci-Tech Innovation Board under specific conditions [3] Group 2 - The Ministry of Industry and Information Technology has outlined ten key tasks for 2026, including addressing "involution" competition and supporting artificial intelligence initiatives [4] - The industrial economy is projected to grow by 5.9% in 2025, with digital industry revenue expected to increase by around 9% [4] - The National Bureau of Statistics has confirmed that China's GDP for 2024 is 13.48 trillion yuan, with a year-on-year growth of 5.0% [4] Group 3 - The A-share market experienced a slight increase, with the Shanghai Composite Index rising by 0.10% to 3963.68 points, marking an eight-day winning streak [6] - The PBOC and the State Administration of Foreign Exchange have clarified that funds raised from overseas listings can be repatriated in foreign currency or RMB [7] - The China Securities Regulatory Commission is taking strict measures against *ST Chang Pharmaceutical for serious financial fraud, proposing fines and initiating delisting procedures [7] Group 4 - The first batch of national-level zero-carbon parks has been announced, with 52 parks expected to generate a total output value of 3.54 trillion yuan [5] - The Ministry of Finance and other departments have issued guidelines to enhance the role of government financing guarantee systems in supporting labor-intensive small and micro enterprises [5] - The PBOC has included agricultural facilities and clearly owned livestock in the scope of agricultural rural mortgage financing to promote rural revitalization [5]

Group 1: Economic Impact and Market Trends - The return of the La Niña phenomenon is expected to disrupt global agricultural supply chains, potentially leading to economic losses of several hundred billion dollars [2][7] - In 2025, the U.S. stock market saw significant gains across major indices, driven by AI-themed trading, with predictions of a further 20% increase in technology stocks in 2026 [3][8] - The high-end residential market in China experienced a unique trend in 2025, with notable sales such as the Shanghai project selling 64 units for a total of 40.25 billion yuan, although a rational return in transactions is anticipated for 2026 [4][9] Group 2: Corporate Developments - Two employees from CITIC Securities were sentenced for bribery, with one receiving a 10-year and 2-month sentence and the other a 10-year and 6-month sentence [2][7] - Shengyuan Environmental Protection reported a significant loss of 81.54% on a 60 million yuan investment in a private equity product, which may impact its 2025 financial performance [2][7] - Baihua Pharmaceutical is planning a change in control, leading to a temporary suspension of its stock trading [3][9] - The National Venture Capital Guidance Fund has been launched, expected to reach a scale of one trillion yuan, aimed at increasing investment in emerging industries [5][9]

Group 1 - The core point of the news is that Baihua Pharmaceutical (600721) is planning a share transfer that may lead to a change in control of the company, as notified by its major shareholders [1] - The company has announced a temporary suspension of its stock trading starting December 29, 2025, for up to two trading days to ensure fair information disclosure and protect investor interests [1] - Baihua Pharmaceutical's main business includes early drug discovery, CMC development, clinical trials, registration applications, and various pharmaceutical services, providing a comprehensive outsourcing and technology transfer service [1] Group 2 - For the first three quarters of 2025, Baihua Pharmaceutical reported revenue of 298.6 million yuan, a year-on-year increase of 2.74%, and a net profit of 32.67 million yuan, up 36.41% year-on-year [3] - The company's stock price increased by 6.54% and 5.88% on December 25 and 26, respectively, closing at 12.24 yuan per share, with a total market capitalization of 4.707 billion yuan [3] - The company's business model is based on pharmaceutical research and clinical trials, providing integrated services to meet diverse and personalized technical requirements of clients, thereby generating revenue [2]